Effect of Levofloxacin and moxifloxacin on arsenic metabolism and cardiotoxicity in APL patients treated with arsenic trioxide.
Antibiotic choice affects how the body processes arsenic therapy in blood cancer, providing actionable guidance for doctors.
This study characterizes how co-administration of fluoroquinolone antibiotics with arsenic trioxide in APL patients affects arsenic metabolism and cardiac toxicity risk, providing clinically actionable drug interaction data for a commonly encountered clinical scenario in APL management. The findings inform antibiotic selection in APL patients who require both ATO therapy and fluoroquinolone prophylaxis.
What the study was
- Study design
- Clinical pharmacology study (human patients)
- Population
- APL patients treated with arsenic trioxide
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Biochem Pharmacol
Why it surfaced
Clinically actionable pharmacological data on fluoroquinolone + arsenic trioxide drug interaction in APL — a common clinical dilemma. Confidence reduced (medium) as sample size not visible from title/abstract alone.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.